← 返回

癌症免疫治疗的最新进展:现状与挑战概述

英文原题:Recent progress in cancer immunotherapy: Overview of current status and challenges.

查看英文原题

Recent progress in cancer immunotherapy: Overview of current status and challenges.

PubMed 2022/11/24(内容时间) Pathol Res Pract Q1 · IF 3.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

癌症治疗目前是医学科学中最重要的挑战之一。手术、化疗、放疗或联合这些方法被用于消除肿瘤。激素治疗、骨髓移植、干细胞治疗以及免疫治疗是其他著名的治疗方式。免疫治疗作为最重要的补充方法,利用免疫系统在手术、化疗和放疗之后治疗癌症。这种方法被系统地用于预防恶性肿瘤的发展,主要通过增强抗肿瘤免疫细胞的激活,并反过来以对健康细胞最低的负面影响来削弱其耗竭。主动免疫治疗可以通过直接使用免疫系统的成分并激活免疫反应来用于癌症免疫治疗。另一方面,被动免疫治疗通过间接诱导并使用由单克隆抗体组成的基于免疫细胞的产品来实施。已强烈证明,免疫治疗与其他治疗手段(如抗血管生成剂)的联合治疗可能是治疗癌症的合理方案。在此,我们聚焦于关于使用免疫检查点抑制剂(ICIs)、过继细胞转移(ACT)和癌症疫苗单独或与其他方法联合治疗癌症的治疗优点的最新发现。此外,我们简要介绍该领域的当前挑战。

展开英文摘要原文

Cancer treatment is presently one of the most important challenges in medical science. Surgery, chemotherapy, radiotherapy, or combining these methods is used to eliminate the tumor. Hormone therapy, bone marrow transplantation, stem cell therapy as well as immunotherapy are other well-known therapeutic modalities. Immunotherapy, as the most important complementary method, uses the immune system for treating cancer followed by surgery, chemotherapy, and radiotherapy. This method is systematically used to prevent malignancies development mainly via potentiating antitumor immune cells activation and conversely compromising their exhaustion with the lowest negative effects on healthy cells.

Active immunotherapy can be employed for cancer immunotherapy by directly using the ingredients of the immune system and activating immune responses. On the other hand, inactive immunotherapy is utilized by indirect induction and using immune cell-based products consisting of monoclonal antibodies. It has strongly been proved that combination therapy with immunotherapies and other therapeutic means, such as anti-angiogenic agents, could be a rational plan to treat cancer.

Herein, we have focused on recent findings concerning the therapeutic merits of cancer therapy using immune checkpoint inhibitors (ICIs), adoptive cell transfer (ACT) and cancer vaccine alone or in combination with other approaches. Also, we offer a glimpse into the current challenges in this context.

论文信息

作者
Darvishi M、Tosan F、Nakhaei P、Manjili DA、Kharkouei SA、Alizadeh A、Ilkhani S、Khalafi F
第一作者单位
Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Department of Aerospace and Subaquatic Medicine, AJA University of Medicinal Sciences, Tehran, Iran. Electronic address: darvishi1349@gmail.com.Iran
通讯作者单位
Faculty of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran. Electronic address: Ghshafagh@gmail.com.Iran
文献类型
综述
期刊
Pathology, research and practice2023 Jan
原文标识
PubMed 36543080 · DOI 10.1016/j.prp.2022.154241